Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma

12Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

High-dose interleukin-2 (IL-2) is an available treatment option for patients with metastatic melanoma or renal cell carcinoma, and is associated with sustained complete and partial responses in a subset of patients. IL-2, however, is not devoid of toxicities, most of which involve the cardiovascular system and manifest as hypotension, arrhythmias, and cardiomyopathy. This report describes an unusual presentation of takotsubo cardiomyopathy in a postmenopausal woman receiving high-dose IL-2 for metastatic melanoma.

Cite

CITATION STYLE

APA

Damodaran, S., Mrozek, E., Liebner, D., & Kendra, K. (2014). Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma. JNCCN Journal of the National Comprehensive Cancer Network, 12(12), 1666–1670. https://doi.org/10.6004/jnccn.2014.0168

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free